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Sonicated albumin has been proposed as a near ideal 
echocardiographic contrast agent with little myocardial 
toxicity or hemodynamic effect. Its use has not yet been 
reported in humans, partly because of difficulties in prep- 
aration. With use of the newly modified sonication method, 
10 ml of 5% albumin was sonicated for 75 s with a 5.0 ml 
slow infusion of air. This resulted in microbubbles with a 
mean diameter (2 1 SD) of 5 * 3 pm. 
Fourteen patients undergoing routine coronary angiog- 
raphy were studied. One patient had normal coronary 
arteries; the other 13 bad significant coronary artery dis- 
ease. In a subgroup of nine patients, sonicated albumin and 
sonicated diatrizoate meglumine sodium (microbubble di- 
ameter 9 f 3 pm) were injected several minutes apart, 
using the same technique. Videodensity-time curves were 
obtained from a region of interest in the myocardium. 
Corrected peak contrast intensity (baseline contrast inten- 
sity subtracted from peak contrast intensity, gray scale 
U/pixel) for sonicated albumin and for sonicated diatrizoate 
meglumine sodium was 51 + 26 and 52 f 19, respectively 
(p = 0.89). Washout half-time (T1/2) for the two agents was 
5.5 f 4.5 and 16.0 2 12.2 s, respectively (p = 0.01). One 
patient with unstable angina experienced transient chest 
pain after repeated albumin injections. No electrocardio- 
graphic changes, blood pressure changes or wall motion 
abnormalities were observed. 
Administered by intracoronary injection, sonicated 5% 
albumin is a safe and effective echocardiographic contrast 
agent for myocardial perfusion imaging, yielding excellent 
myocardial contrast with physiologic washout time. 
(.I Am Co11 Cardioll989;14:660-5) 
Since Armstrong (I) and Meltzer (2) and their coworkers 
reported on myocardial perfusion imaging by contrast echo- 
cardiography in animals in 1982 and Santoso et al. (3) 
initially described such imaging in humans in 1985, there has 
been increasing interest in myocardial perfusion imaging by 
contrast echocardiography. A major obstacle to this type of 
research has been the absence of an easily available, safe 
and effective echocardiographic contrast agent. Feinstein et 
al. (4) introduced the use of ultrasonic energy for microbub- 
ble preparation. Microbubbles produced by sonication are 
significantly smaller than those produced by hand agitation 
(5). The ideal myocardial echocardiographic contrast agent 
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should have no myocardial or hemodynamic toxic effects 
and should feature highly uniform and echogenic microbub- 
bles that could pass through the microcirculation (6). Soni- 
cated or agitated diatrizoate meglumine sodium does not 
satisfy these requirements (7-10). On the basis of animal 
studies, sonicated albumin has been proposed as a more 
ideal contrast agent with neither a hyperemic response nor 
significant hemodynamic effects (11). Keller et al., using 
microcirculation of the golden hamster cheek pouch, found 
that microbubbles produced by sonication of 5% albumin 
have the same behavior as red blood cells (12). When these 
workers assessed the pathologic effects of sonicated albumin 
on the myocardium, brain and kidneys in rabbits, they found 
that nonphysiologic high doses caused microinfractions in 
the brain and myocardium (13). Smaller doses had no 
adverse effects. 
Until now, the use of sonicated albumin has been limited 
to several centers, probably because of difficulties in its 
preparation. We modified the method of sonication by intro- 
ducing a “sonicating chamber” (Fig. I). Using this method, 
0735.1097189153.50 
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-<#$I” stopcock 
air injection 
Figure 1. The sonication chamber with the sonicator horn inserted. 
we assessed the safety and efficacy of sonicated albumin in 
14 patients undergoing coronary angiography. In a subgroup 
of nine patients, sonicated albumin was compared with 
sonicated diatrizoate meglumine sodium. 
Methods 
Study patients (Table 1). With approval of the human 
subjects committee of this institution and after giving in- 
formed consent, 14 patients undergoing routine coronary 
angiography were studied. The first patient had normal 
coronary arteries and the next 13 had significant coronary 
artery disease (270% stenosis in one or more major coro- 
nary vessels). There were eight men and six women, aged 37 
to 70 years (mean t 1 SD 54 2 9). The indication for 
coronary angiography was angina in eight patients (unstable 
in three), and myocardial infarction in the other six patients. 
A left anterior descending coronary artery lesion was 
present in eight patients, right coronary artery stenosis in 
five and left circumflex stenosis in four. 
Echo contrast agents. Sonicated 5% human albumin 
(American Red Cross) and diatrizoate meglumine sodium 
were used as echo contrast agents prepared with use of a 
model W-375 sonicator (Heat System, Inc.) with frequency 
of 20 kHz. A sonicating chamber that permits simple bedside 
manufacture of contrast agents was used to prepare each 
agent (14) (Fig. 1). For sonication of albumin, an energy 
output setting of 8 was used. The sonicating chamber was 
filled with 10 ml of albumin and a V’z in. (1.27 cm) horn was 
placed 3 to 4 mm above the tip of the needle used to inject air 
into the sonicating chamber. Then two steps were followed: 
1) initial sonication was performed for 60 s to heat the 
solution; 2) 5 ml of air was injected through the needle 
against the activated horn during the immediately subse- 
quent 15 s. With use of this method of sonication, the 
albumin was separated into two layers: a lower clear layer 
and an upper foamy layer. The mixture of both layers diluted 
with 10 ml of nonsonicated human albumin was used for 
injection. 
For sonication of diatrizoate meglumine sodium, 8 ml was 
placed in the sonicating chamber and an energy output of 7 
was used. Total sonication time was 20 s. 
Intracoronary injection protocol. The volume injected 
was calculated by adding 3 ml to the dead space for left 
coronary artery injections and 2 ml to the dead space for 
right coronary artery injections. Injections were made by 
hand through the standard coronary catheters. Sonicated 
albumin was injected 3 to 5 min after sonication and soni- 
cated diatrizoate meglumine sodium was injected immedi- 
ately after sonication. No flushing or withdrawal was done 
during recording. All injections were made by the same 
person (L.S.O.). The five initial patients had repeated injec- 
tions of sonicated human albumin. In the last nine patients, 
Table 1. Characteristics of 14 Patients 
Patient Age (yr) Clinical 
No. Gender Presentation Coronary Anatomy (% ) 
1 48 M Angina Normal 
2 66F AMI, post &PA LAD 95% 
3 56 F Angina RCA 9O%, LAD 70% 
4 46M Unstable angina RCA 90% 
5 57 M AMI LCX l@l% 
6 48 M Unstable angina LAD 95%, LCx 90% 
I 50 M AMI. post rt-PA LCX 90% 
8 59 F Unstable angina RCA 90% 
9 52 M Angina LAD 95% 
10 55 F AMI, post R-PA LAD 90% 
11 66M AMI. post SK RCA 80% 
12 45 F Angina RCA 80 to 90%, LAD 70% 
13 70 F AM1 LAD 70 to 80% 
14 37 M Angina LAD 70%, LCx 99% 
AMI = acute myocardial infarction: F = female: LAD = left anterior descending coronary artery; LCx = 
circumflex artery; M = male: RCA = right coronary artery; e-PA = recombinant tissue-type plasminogen activator; 
SK = streptokinase. 
Fi
gu
re
 2
. 
St
op
 f
ra
m
e 
pa
ne
ls
 s
ho
w
in
g 
co
nt
ra
st
-e
nh
an
ce
d 
ec
ho
ca
rd
io
gr
am
s 
(a
rr
ow
s)
 a
nd
 t
he
 o
ut
lin
ed
 a
re
as
 f
ro
m
 w
hi
ch
 v
id
eo
 i
nt
en
si
ty
 w
as
 d
et
er
m
in
ed
. 
Pa
ra
st
em
al
 
lo
ng
-a
xi
s v
ie
w
 b
ef
or
e 
(a
) a
nd
 a
fte
r 
(b
) 
in
tra
co
ro
na
ry
 i
nj
ec
tio
n 
of
 s
on
ic
at
ed
 a
lb
um
in
; p
ar
as
te
m
al
 s
ho
rt-
ax
is
 v
ie
w
 b
ef
or
e 
(c
) a
nd
 a
fte
r 
(d
) 
co
nt
ra
st
 i
nj
ec
tio
n.
 A
pi
ca
l f
ou
r 
ch
am
be
r v
ie
w
 b
ef
or
e 
(e
) a
nd
 a
fte
r 
(f
J c
on
tra
st
 i
nj
ec
tio
n;
 a
pi
ca
l t
w
o 
ch
am
be
r 
vi
ew
 b
ef
or
e 
(g
) a
nd
 a
fte
r 
(h
) c
on
tra
st
 i
nj
ec
tio
n.
 C
x 
= 
ci
rc
um
fle
x 
ar
te
ry
 t
er
rit
or
y;
 L
A
D
 =
 le
ft 
an
te
rio
r 
de
sc
en
di
ng
 c
or
on
ar
y 
ar
te
ry
 t
er
rit
or
y;
 P
D
A
 =
 p
os
te
rio
r 
de
sc
en
di
ng
 a
rte
ry
 t
er
rit
or
y;
 R
C
A
 =
 r
ig
ht
 c
or
on
ar
y 
ar
te
ry
 t
er
rit
or
y.
 
JACC Vol. 14. No. 3 REISNER ET AL, 
September 1989:66&5 
663 
MYOCARDIAL CONTRAST ECHO BY SONICATED ALBUMIN 
sonicated albumin and sonicated diatrizoate meglumine so- 
dium were injected several minutes apart, using the same 
technique. 
Echocardiographic technique. Patients were studied in 
the supine position. An Ausonics MicroImager scanner was 
used equipped with a 3.5 MHz transducer. The transducer 
and gain controls were kept unchanged during each study. 
Recording started before injection and continued until com- 
plete disappearance of contrast. Echocardiographic views 
that were employed were chosen according to the coronary 
artery studied. For proximal left anterior descending or 
circumflex lesions, the parasternal short-axis view at mid- 
papillary muscle level, a parasternal long-axis view or an 
apical four chamber view was used. For mid-left anterior 
descending lesions (after the take-off of the first septal 
branch), the apical four chamber view was always used. For 
the right coronary artery, a parasternal short-axis or apical 
two chamber view, or both, was used. 
Evaluation of toxicity. The patient was asked to inform 
the operator about any symptoms such as chest pain, dys- 
pnea, palpitation, nausea or dizziness during the catheter- 
ization. Blood pressure and heart rate were recorded by an 
external automatic cuff manometer before and immediately 
after each injection. Electrocardiographic (ECG) changes 
(from a single monitored lead V,) were recorded. Wall 
motion abnormalities were visually analyzed from recorded 
videotapes independently from contrast analysis by a single 
observer. 
Data Analysis 
Two-dimensional echocardiography. Corrected contrast 
intensity (baseline contrast intensity subtracted from peak 
contrast intensity in gray scale U/pixel) was analyzed off line 
with use of a Microsonics Datavue system. Echocardio- 
graphic frames were operator-selected by freezing the de- 
sired image at end-diastole synchronized to the peak of the R 
wave on the ECG. The largest possible area of interest was 
traced, based on the entire territory of the coronary artery 
being studied and the echocardiographic view used, omitting 
the endocardial and epicardial borders and papillary muscles 
(Fig. 2). In the short-axis view, left anterior descending 
artery territory was separated from left circumflex artery 
territory by a borderline marked at the 2 o’clock position. 
Right coronary artery territory was defined as the inferior 
wall and inferior septum. In the apical two chamber view, 
right coronary artery territory included the inferior wall and 
posteromedial papillary muscle. In the parastemal long-axis 
view, the septum was considered as left anterior descending 
artery territory, and the posterior wall as right coronary 
artery territory, with variations according to left versus right 
dominance. In the four chamber view, the septum was 
considered as left anterior descending artery territory, and 
the lateral wall as left circumflex artery territory. The left 
ventricular apex was the area of interest in mid-left anterior 
descending artery lesions. 
Myocardial contrast washout curves. These curves were 
generated from the area of interest with use of beat by beat 
analysis of frozen end-diastolic frames. Corrected contrast 
intensity was plotted on the vertical axis and time on the 
horizontal axis. Peak contrast intensity for each injection 
was determined as the highest point of the curve. Washout 
half-time (Tl/2) was calculated from the decay phase of the 
curve with use of the least square fit by the equation T112 = 
In2ik (where In = natural logarithm and k = exponential 
decay rate) (15). No smoothing of curves was performed. 
For the final analysis, poor quality (noisy) curves were 
excluded if the correlation coefficient of the videodensity 
versus time decay curve was <0.75. 
Statistical analysis. Paired Student’s t tests were used to 
compare values of peak contrast intensity and washout 
half-time (Tli2) between sonicated diatrizoate meglumine 
sodium and sonicated albumin values are given as mean 
values ‘- 1 SD. 
Results 
Contrast agents. Sonication of albumin resulted within 
30 s in separation into two distinct layers: a lower clear layer 
with microbubble size of 1.9 k 0.4 and an upper foamy layer 
with microbubble size of 4 to 9 pm. The mixture of both 
layers yielded microbubble size of 5.2 t 2.6 pm (based on 10 
different sonications measured by Coulter Counter). The 
sonication of diatrizoate meglumine sodium resulted in 
a suspension of microbubbles with a diameter of 
9 2 3 pm (by light microscopy [ 141). 
Safety. Thirty-eight injections of sonicated albumin were 
performed in the 14 patients resulting in 2.7 ? 2.0 injections 
per patient, with a mean of 7.7 * 6. I ml of sonicated albumin 
per patient. One patient, with unstable angina, experienced 
transient chest pain after repeated albumin injection. No 
ECG changes, blood pressure changes or wall motion abnor- 
malities were observed. 
Efficacy (Table 2). Sonicated albumin yielded excellent 
myocardial contrast during repeated intracoronary injections 
in the five initial patients (Fig. 2). In the last nine patients, 
the efficacy of sonicated albumin and sonicated diatrizoate 
meglumine sodium was compared. Corrected peak contrast 
intensity (baseline contrast intensity subtracted from peak 
contrast intensity: gray scale U/pixel) for sonicated albumin 
and for sonicated diatrizoate meglumine sodium was 5 I k 26 
(range I7 to 95) and 52 + 19 (range 18 to 75), respectively. 
This was not statistically different (p = 0.89). 
Segmentul hypoperfusion (minimal or no contrast) in the 
potentially ischemic segment according to coronary artery 
disease distribution was seen in six patients. Three patients 
(cases 2, 6 and 10) with a severe lesion (90 to 95% stenosisj 
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Table 2. Peak Contrast Intensity and Washout Half-Time 
in 10 Patients 
50% 
Albumin 
(ll = IO) 
Me&mine 
Sodurn 
In = 101 p Value 
Peak intensity 
(gray scale level 
U/pixel) 
T112 is) 
51 + 26 51 ? 19 0.89 
5.5 + 4.5 16.0 t I?.? 1).015 
p value by paired Student’s f test; Tli? = washout half time. 
of the left anterior descending artery had an enhancement of 
the proximal interventricular septum with no or partial 
enhancement of the midseptal area and no enhancement of 
the apical segment. One patient (case 4) with a 90% lesion in 
a dominant right coronary artery had a contrast study before 
and after successful coronary angioplasty. In the postangio- 
plasty study, the posterior wall had a significantly higher 
contrast intensity. Two patients (cases 5 and 7) with a 90%’ 
and lOtI?& stenotic lesion, respectively, of the circumflex 
artery had a filling defect in the lateral wall. 
Myocardial contrast washout curves (Table 2, Fig. 3). 
Twenty (59%) of 34 paired washout curves obtained in six of 
nine patients studied were good quality curves (defined as 
correlation coefficient r > 0.75) for both sonicated albumin 
and sonicated diatrizoate meglumine sodium. Washout half- 
time (Tl/2) for sonicated albumin was significantly shorter 
(5.5 i. 4.5 s) than that for sonicated diatrizoate meglumine 
sodium (16.0 + 12.2 s) (p = 0.015). 
Discussion 
Sonicated albumin as a contrast agent for myocardial 
perfusion imaging. Sonicated diatrizoate meglumine so- 
dium, the most common myocardial echo contrast agent 
described to date in humans, is far from being an ideal 
contrast agent. Sonicated albumin has been proposed as a 
better contrast agent in animals, but until now there has been 
no experience in humans. This report is the first to describe 
use of intracoronary sonicated albumin in humans and the 
study group includes patients with severe coronary artery 
disease. The sonication chamber technique described here 
and in Reference 14 provides a simple and reliable bedside 
method of producing microbubbles in different carrier solu- 
tions including 5% albumin. The resulting microbubbles are 
small, stable and echogenic. Human albumin is a sterile, 
nonpyrogenic solution that is isoosmotic with human 
plasma. As has been shown by Keller et al. (I I) in an animal 
preparation, we found that sonicated albumin is as cffectivc 
as sonicated diatrizoate meglumine sodium in humans, yield- 
ing excellent myocardial contrast (Table 2). Washout half- 
time was shorter for sonicated albumin than for diatrizoate 
meglumine sodium, probably indicating smaller microbubble 
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Figure 3. a, Typical contrast washout curve? for sonicated albumin 
and sonicated meglumine sodium. b, The vertical axis is converted 
into a logarithmic scale (see text for details). Note the longer 
washout time for diatrizoate me&mine sodium. 
size with physiologic capillary transit and less “hangup” of 
microbubbles in the microcirculation. The shorter natural 
decay of sonicated diatrizoate meglumine sodium may 
shorten its half-time and make these results even more 
significant. 
The safety of myocardial contrast echocardiography in 
humans has been established in several studies (3,16-18). 
Our study group consisted of patients with severe, fre- 
quently unstable, coronary artery disease. Even in this 
group with unstable disease, no significant side effects were 
noted during intracoronary injection of either echocardio- 
graphic contrast medium. 
Analysis of segmental contrast enhancement according to 
normal versus potentially ischemic segments was per- 
formed. In some patients, hypoperfusion could be suspected 
by the decrease in enhancement of the segments supplied by 
a severely stenosed coronary vessel. However, the overall 
number of observations is small. The primary goal of myo- 
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cardial contrast echocardiography remains to enhance the 
myocardium after a peripheral vein injection of a contrast 
agent. Despite the recent success of imaging the left heart 
cavities after a peripheral vein injection of sonicated albu- 
min, the enhancement of myocardium is still rare (I 3). 
We note that a commercial preparation of microbubbles 
in human albumin is currently undergoing animal and clinical 
testing (Albunex@, MB1 Inc.). This may or may not be 
similar to the sonicated albumin described in the current 
study, but to avoid confusion, we wish to clarify that our 
work has been independent of MB1 and not supported by 
them. 
Limitations. A conceptual limitation to toxicity studies is 
that they are prone to “beta errors”: the hypothesis of 
absolute safety can never be proved with absolute certainty. 
Therefore, our negative data are reassuring and useful but 
cannot prove absolute safety. It is possible that different 
methods could measure toxicity that was missed by our 
protocol. We have recently shown (10) that sonicated diatri- 
zoate meglumine sodium can cause subtle transient mechan- 
ical toxicity in an animal model. 
Conclusions. Sonicated human albumin is relatively safe 
and is an effective contrast agent for myocardial contrast 
echocardiography in humans. Injected into a coronary ar- 
tery, it yielded excellent contrast with a physiologic washout 
time. The sonication method and chamber described in this 
report permit simple bedside manufacture of microbubbles 
in human albumin. These microbubbles are small, stable and 
echogenic. 
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